| P50 | author | Khalid S Khan | Q58066939 |
| P2093 | author name string | Jie Li | |
| | Xiu Yu | |
| | Qi He | |
| | Minjie Guan | |
| | Xuanwen Weng | |
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| | Adaptive Immune Resistance: How Cancer Protects from Immune Attack | Q26798448 |
| | Cancer statistics, 2012 | Q27860574 |
| | Operating characteristics of a rank correlation test for publication bias | Q27860653 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses | Q27860840 |
| | The blockade of immune checkpoints in cancer immunotherapy | Q27860852 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Erlotinib in previously treated non-small-cell lung cancer | Q29547546 |
| | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 |
| | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 |
| | Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. | Q34272038 |
| | Treatment of advanced non small cell lung cancer | Q35667817 |
| | Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines | Q36412597 |
| | Future options for ALK-positive non-small cell lung cancer. | Q38324332 |
| | The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer | Q38768030 |
| | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 |
| | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 |
| | Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance | Q58575896 |
| | Heterogeneity testing in meta-analysis of genome searches | Q81128804 |
| | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | Q88973544 |
| | Management of Brain Metastases in the New Era of Checkpoint Inhibition | Q91021412 |
| | Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer | Q95375604 |
| | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Q40408396 |
| | Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status | Q44273853 |
| | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 |
| | Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies | Q47620549 |
| | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | Q47834638 |
| | Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer | Q47884056 |
| | Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence? | Q49773079 |
| | Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases | Q50161502 |
| | An Address ON ACUTE ABDOMINAL SYMPTOMS: Delivered before the Walthamstow Division of the Metropolitan Counties Branch of the British Medical Association | Q50318446 |
| | Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. | Q51372253 |
| | Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. | Q52586557 |
| | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. | Q52586565 |
| | Cancer immunotherapy using checkpoint blockade. | Q52641912 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| | systematic review | Q1504425 |
| | Immune Checkpoint Inhibitors | Q59649873 |
| | Randomized Controlled Trials | Q56855364 |
| P304 | page(s) | 1623-1629 | |
| P577 | publication date | 2019-02-18 | |
| P1433 | published in | Cancer Management and Research | Q5031417 |
| P1476 | title | Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials | |
| P478 | volume | 11 | |